NOVO NORDISK vs ELI LILLY: Chi vince la GUERRA del Dimagrimento? (CONFRONTO ELY LILLY)

Summary

In this video, the speaker compares the financial and competitive positions of two major pharmaceutical companies, Novo Nordisk and Eli Lilly, particularly in the obesity and diabetes drug market. Novo Nordisk faces challenges due to increased competition and market uncertainty, while Eli Lilly, with its more aggressive growth, has capitalized on these shifts. The discussion highlights differences in their products, market strategies, and growth trajectories. While Eli Lilly is currently outperforming, the speaker suggests that Novo Nordisk could surprise the market if it manages to recover. The video offers insights into the future of the weight-loss drug market and its potential risks.

Takeaways

• 😀 Novo Nordisk remains a highly discussed company in Europe despite geopolitical challenges, such as tensions with the US and issues related to Greenland.
• 📉 Novo Nordisk's stock has suffered due to increased competition, particularly from Eli Lilly, and concerns about adverse effects related to its GLP-1 drug (semaglutide).
• 🩺 Novo Nordisk is heavily reliant on obesity and diabetes drugs, with 93% of its revenue coming from these treatments, making it vulnerable to changes in market growth or competition.
• ⚠️ The growth in sales of semaglutide has slowed down significantly, with Q4 2024 marking a peak followed by a sharp drop in growth from 30% to 5%.
• 🔬 Increased competition from generic versions and pharmacy compounding of GLP-1 drugs has created challenges for Novo Nordisk, impacting its market share.
• 🇺🇸 The US healthcare system is also complicating matters, with countries potentially bypassing Novo Nordisk’s drugs in favor of cheaper alternatives from US companies, like Eli Lilly.
• 💡 Eli Lilly is outperforming Novo Nordisk due to its ability to scale production more efficiently and offer alternative obesity treatments, such as tirzepatide.
• 💥 Eli Lilly benefits from having a different active ingredient (tirzepatide) compared to Novo Nordisk’s semaglutide, protecting it from shortages that affect Novo Nordisk's drugs.
• 💊 Novo Nordisk still leads in oral obesity drugs, but Eli Lilly has stronger performance in injectable drugs, making it more competitive in the market.
• 📈 Eli Lilly has a significantly higher market valuation and growth potential compared to Novo Nordisk, with analysts expecting greater growth for Lilly at current valuations.
• 💭 While Eli Lilly’s future seems more secure with higher growth expectations, Novo Nordisk could potentially surprise the market if it recovers and grows faster than anticipated, particularly if the weight loss market proves to be a long-term trend.

Q & A

Why has Novo Nordisk struggled recently?

Novo Nordisk has faced challenges primarily due to a slowdown in the growth of its GLP-1 drugs, which account for 93% of its revenue. The company has also been impacted by increased competition and concerns about the adverse effects of its flagship drug, Ozenpacovin, and the GLP-1 class in general.

What role do geopolitical factors play in the struggles of Novo Nordisk?

Geopolitical issues, such as tensions with the United States under Trump and the situation surrounding Greenland, have added to the uncertainty around Novo Nordisk. These factors may have contributed to the company's challenges in maintaining growth and market confidence.

How does competition affect Novo Nordisk's position in the market?

Increased competition, especially from generic and compounded drug producers, has hurt Novo Nordisk. These producers can create similar drugs with slight modifications, bypassing the regulatory approval process, which results in lower costs and increased market saturation.

What is the significance of the Food and Drug Administration (FDA) in the struggles of Novo Nordisk?

The FDA played a crucial role in Novo Nordisk's problems by causing a drug shortage, which led to a significant slowdown in the company's growth. This shortage exacerbated the competitive pressure on Novo Nordisk and its ability to meet market demands.

How has Eli Lilly positioned itself as a competitor to Novo Nordisk?

Eli Lilly has successfully capitalized on the obesity drug market by offering alternatives like Zibbound and Monjaro. They have also used economies of scale to avoid the issues Novo Nordisk faced, including drug shortages and the competitive edge with a different active ingredient (tirzepatide).

What is the advantage of Eli Lilly's drug, Monjaro, compared to Novo Nordisk’s offerings?

Monjaro, which uses tirzepatide instead of semaglutide, has benefited from being immune to the semaglutide shortage, giving it a competitive edge. It has also been marketed effectively, especially with celebrity endorsements, making it popular in the weight-loss market.

Why did Eli Lilly’s growth in the obesity drug market accelerate?

Eli Lilly's growth was driven by its ability to produce tirzepatide in large quantities, effectively meeting the demand that Novo Nordisk could not fulfill due to supply issues. Additionally, its positioning in the U.S. market, including less price pressure due to tariffs, has given it a strategic advantage.

What are the key differences between Novo Nordisk’s and Eli Lilly’s drugs?

Novo Nordisk offers oral medications with a promising pipeline of future drugs, while Eli Lilly is stronger in injectable drugs, which are more effective for both diabetes and weight loss. The key difference lies in the route of administration and their respective market focus.

Why might Novo Nordisk be a better investment than Eli Lilly despite recent struggles?

Novo Nordisk may be a better investment because its stock has already absorbed much of the negative news, meaning expectations are low. If the company were to exceed those low expectations or recover its growth, its stock could see significant gains, whereas Eli Lilly is already priced with high expectations.

What are the potential health risks associated with these obesity drugs?

Obesity drugs, particularly those in the GLP-1 class like semaglutide, have been associated with various side effects, including issues like vision problems, muscle loss, and internal organ damage due to metabolism changes. These side effects could potentially lead to legal and reputational risks for the companies involved.